RMH - CAR-T Treatment

A Contract Award Notice
by THE ROYAL MARSDEN NHS FOUNDATION TRUST

Source
Find a Tender
Type
Contract ()
Duration
not specified
Value
£380K
Sector
MISCELLANEOUS
Published
24 Oct 2025
Delivery
not specified
Deadline
n/a

Related Terms

Location

Geochart for 1 buyers and 1 suppliers

1 buyer

1 supplier

Description

CAR-T treatment called Obecel developed to treat relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r B-ALL) which has recently become available to patients. The decision which treatment is most suitable applicable to a specific age group is a clinical one that would be decided by a Multi-Disciplinary Team (MDT). The product should meet strict NHS England standards for cryogenic storage and handling and RMH has such credentials.

Award Detail

1 Unnamed (None)
  • RMH - CAR-T Treatment
  • Reference: 1
  • Value: £380,000

CPV Codes

  • None found

Other Information

** PREVIEW NOTICE, please check Find a Tender for full details. **

Reference

  • ocds-h6vhtk-05d335
  • FTS 068116-2025

Domains